DRB436

An open label, multi-center roll-over study to assess longterm effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)

An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatment.